The goal of my lab’s research is to investigate the contribution extracellular (exosomal) survivin makes to the resistance of cancers to stress-induced cell death in the tumor microenvironment. Specifically, we are identifying the functional role of survivin in promoting cancer cell survival in the presence of stress as well as investigating the functional significance of exosomal release of survivin from stressed cancer cells. The paradigm shift to focus less on the autonomous functions of the cancer cell and more on the heterotypic interactions that go on in the tumor microenvironment is a niche that allows my lab to define itself in a manner that doesn’t directly compete with established survivin investigators. We have thus laid the groundwork for our research by developing effective measures of characterizing the release of survivin to the extracellular space, the uptake of survivin into cancer cells and surrounding non-cancer cells, and its proliferative and therapy resistance-inducing mechanisms.
Center for Health Disparities: http://www.llu.edu/health-disparities/faculty/wall.page?
1. Khan S, Ferguson Bennit H, Wall NR. The Emerging Role of Exosomes in Survivin Secretion. Histology and Histopathology, Accepted for Publication, 2014.
2 .Valenzuela MMA, Neidigh JW, Wall NR. Antimetabolite treatment for Pancreatic Cancer. Chemotherapy, 3(3): 1-7, 2014.
3. Aspe JR, Diaz Osterman CJ, Jutzy JMS, Deshields S, Whang S, Wall NR. Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant. J Extracellular Vesicles, 3: 1-9, 2014.
4. Khan S, Ferguson H, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. Early diagnostic value of Survivin and its alternative splice variants in breast cancer. BMC Cancer, 14(1):176, 2014.
5. Galloway NR, Diaz Osterman CJ, Reiber K, Jutzy JMS, Li F, Sui G, Soto U, Wall NR. Ying Yang 1 regulates the transcriptional repression of Survivin. Biochemical and Biophysical Research Communications, 445(1): 208-213, 2014.
6. de Necochea-Campion R, Chen CS, Mirshahidi S, Howard FD, Wall NR. Clinico-Pathologic Relevance of Survivin Splice Variant Expression in Cancer. Cancer Letters, 339(2): 167-174, 2013.
7. Jutzy JMS, Khan S, Valenzuela MMA, Milford TM, Payne KJ, Wall NR. Tumor-released survivin inhibits T cell proliferation and alters CD4+ T cell cytokine profiles to induce a pro-tumor environment. Cancer Microenvironment, 6(1): 57-68, 2013.
8. Khan S, Jutzy JMS, Valenzuela MMA, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer. PLoS One, 7(10): 1-10, 2012.
9. Khan S, Jutzy JMS, Aspe JR, Valenzuela MMA, Park J, Turay D, Wall NR. The Application of Membrane Vesicles for Cancer Therapy. Book 3, Advances in Cancer Therapy, InTech Publishing 2011, ISBN 978-953-307-703-1.
10. Wall NR. Colorectal cancer screening using protected microRNAs. J Gastrointestinal Oncology, 2: 206-207, 2011.
11. Khan S, Jutzy JMS, Aspe JR, McGregor D, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis, 16(1): 1-12, 2011.
12. Aspe JR and Wall NR. Survivin-T34A: molecular mechanism and therapeutic potential. OncoTargets and Therapy, 3:247-254, 2010.
13. Asumen MG, Ifeacho TV Cockerham L, Pfandl C, Wall NR. Dynamic changes to survivin subcellular localization are initiated by DNA damage. OncoTargets and Therapy, 3:129-137, 2010.
14. Galloway NR, Aspe JR, Sellers C, Wall NR. Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer. Pancreas 38(7) 782-790, 2009.
15. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon M, Langridge W, Wall NR. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. British Journal of Cancer 100(7):1073-1086, 2009.